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Are Cholesterol Treatment Targets a Deterrent to Optimal
Lipid-Lowering Therapy?
David D. Waters, MD
“A good decision is based on knowledge and not on num-
bers” – Plato
History has not been kind to those who assigned num-
bers todefinenormal or optimal cholesterol levels. In the 1963
table of normal laboratory values in theNew England Journal
of Medicine, normal total cholesterol was listed as 150-280
mg/dL (to convert tomillimolesper liter,multiplyby0.0259),1
referenced to an article published in 1916. Because most pa-
tientswithcoronarydisease thushad“normal”cholesterol lev-
els, thehypothesis that cholesterolwasaprimary causeof ath-
erosclerosis facedstiffheadwindsbefore finallybeingaccepted.
TheCholesterol andRecurrent Events (CARE) trialwas an
important and influential early statin trial.Among4159postin-
farctionpatients, those randomized topravastatin40mg/dex-
perienced a 32% reduction in low-density lipoprotein choles-
terol (LDL-C) and a 24% reduction in the primary end point,
coronary death, or myocardial infarction over 5 years of
follow-up.2 Based on an analysis of their data, the authors
opined that although their finding couldnotbe consideredde-
finitiveandrequiredconfirmation, anLDL-C levelof 125mg/dL
maybe anapproximate lower boundary for a clinically impor-
tant influenceof theLDL-C level oncoronarydisease.Mostpa-
tientswithmyocardial infarction presentwith an LDL-C level
of less than 125mg/dL.Fortu-
nately, subsequent trials rap-
idly established that statins
are of benefit to patients af-
ter myocardial infarction irrespective of their LDL-C level.
Early cholesterol guidelinesestablishedspecific cutpoints
both for initiation of treatment and as treatment targets: 190
mg/dL, 160mg/dL, 130mg/dL, 100mg/dL,and later70mg/dL.3
These numbers were eliminated in the 2013 American Col-
lege of Cardiology/American Heart Association cholesterol
treatment guideline but persist in the 2016 European guide-
line and in guidelines fromother countries.3 Clinical trial data
indicate that statins reduce cardiovascular (CV) events across
a broad range of baseline LDL-C, down to a level less than 50
mg/dL,4 and that for each millimoles per liter reduction in
LDL-C, CV events are reduced by 22%.5
Further Cardiovascular Outcomes ResearchWith PCSK9
Inhibition in SubjectsWith Elevated Risk
In this issue, Giugliano et al6 describe the benefits of LDL-C
lowering with evolocumab in high-risk patients with a base-
line LDL-C level of less than 70 mg/dL in the Further Cardio-
vascular Outcomes Research With PCSK9 Inhibition in Sub-
jects With Elevated Risk (FOURIER) trial.6 Overall, 27 564
patients with established vascular disease plus other high-
risk features were randomized to evolocumab or placebo on
top of statin therapy and were followed for a median of 2.2
years.7Treatmentwithevolocumabwasassociatedwitha59%
reduction in LDL-C levels, from a mean of 92 mg/dL to 30
mg/dLanda 15%reduction in theprimaryendpoint (HR,0.85;
95% CI, 0.79-0.92; P < .001). This degree of CV event reduc-
tion is less than expected based on the amount of LDL-C
reduction.8
To be eligible for FOURIER, patients had to have had an
LDL-C level of at least 70 mg/dL or a non–high-density lipo-
proteincholesterol levelofat least 100mg/dLonbaselinestatin
therapy. In thisarticle,6 the2034patientswithabaselineLDL-C
levelof less than70mg/dLarecomparedwithmostof theFOU-
RIERpatientswhohadabaselineLDL-C level of at least 70mg/
dL. As a consequence of the inclusion criterion requiring that
they have a non–high-density lipoprotein cholesterol level of
at least 100mg/dL, the LDL groupwas enrichedwith patients
with diabetes (48.5% vs 35.6%) and the metabolic syndrome
(72.8% vs 58.2%) and had lower levels of high-density lipo-
protein cholesterol (38.5mg/dLvs44.0mg/dL) andhigher tri-
glyceride levels (181 mg/dL vs 131 mg/dL; to convert to milli-
moles per liter, multiply by 0.0113).
Evolocumabreducedtheriskof theprimarycompositeend
point by 20% (HR, 0.80; 95%CI, 0.60-1.07) in patients with a
baselineLDL-C levelof less than70mg/dL, comparedwith 14%
(HR, 0.86; 95% CI, 0.79-0.92) in patients with an LDL-C level
of at least 70 mg/dL. There was no evidence of treatment ef-
fectmodification by baseline LDL-C level. These results indi-
cate that high-risk patientswith anLDL-C level of less than 70
mg/dL benefit from further LDL-C reduction.
Treating to a Target
These results also call into question the validity of specific
LDL-C targets suchas a level of 70mg/dL.Abigger issue is that
although guidelines have recommended for many years that
physicians treat to a specific numerical LDL-C target, this ap-
proach had not been rigorously tested in an adequately sized
clinical trial until now.
In the just presentedbutnot yet publishedStandardvs In-
tensiveStatinTherapy forHypercholesterolemicPatientsWith
Diabetic Retinopathy (EMPATHY) study, 5042 patients in Ja-
panwere randomized to either standard therapy, targeting an
LDL-C level of 100mg/dL to 120mg/dL,or to intensive therapy,
targeting an LDL-C level of less than 70 mg/dL.9 After a me-
dian follow-up of 37 months, the CV event rate was reduced,
butnot significantly, in the intensive therapygroup (HR,0.84;
95% CI, 0.67-1.07; P = .15).
However, less than half of the patients in the intensive
therapy group actually attained theLDL-C goal of less than 70
mg/dL. In a post hoc analysis restricted to patients who
achieved their LDL-C targets, a large reduction in CV events
was observed (HR, 0.48; 95% CI, 0.28-0.82; P = .007).
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The failure ofmore thanhalf of patients to reach their tar-
get of less than 70 mg/dL despite more than 3 years of treat-
mentwithin the strict confines of a clinical trial suggests that
thewhole conceptof treating to target is flawed. Japanesephy-
sicians tend to prescribe smaller doses ofmost drugs, includ-
ing statins, and it is possible that a higher proportion of pa-
tients may have attained goal if the trial was performed
elsewhere. Nevertheless, it seems reasonable for guideline-
writing committees to stop recommending the treating to tar-
get approach until credible evidence shows that it works.
Practical Implications
High-risk patients benefit from aggressive LDL-C lowering
whether their baseline level is greater or less than 70 mg/dL.
Thedegreeof risk reductionwill be lessat lowerbaselineLDL-C
levels because treatment lowers LDL-C as a percentage of the
baseline level,while benefit is proportional to the absolute re-
duction (22% per mmol/L). Proprotein convertase subtilisin/
kexin type 9 inhibitors, such as evolocumab, are usually not
cost-effective at their current price, so statin dose should be
maximized as a first step. New drugs that lower LDL-C levels
nowbeingdevelopedhave thepotential to strengthen anddi-
versify our therapeutic armamentarium.
Low-density lipoprotein cholesterol levels in patients re-
ceving treatment have steadily decreased from significantly
more than 100mg/dL in the early statin trials to 30 mg/dL in
evolocumab-treatedpatients inFOURIER.Perhapspatients at-
tain the maximum benefit from LDL-C lowering at 30 mg/dL
because there is not much room to go lower. We have come a
long way since 1963.
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